Table 1.
Demographic and Clinical Characteristics of Severe GICs Before and After Chemotherapy
| Items | Before Chemotherapy (n= 148) | After Chemotherapy (n=130) | |||||
|---|---|---|---|---|---|---|---|
| No (n=72) | Have (n= 76) | P | No (n=111) | Have (n =19) | P | ||
| Age | ≤65 | 48 (66.7%) | 41 (53.9%) | 0.114 | 71 (64.0%) | 11 (57.9%) | 0.612 |
| >65 | 24 (33.3%) | 35 (46.1%) | 40 (36.0%) | 8 (42.1%) | |||
| Sex | Female | 26 (36.1%) | 29 (38.2%) | 0.797 | 44 (39.6%) | 6 (31.6%) | 0.505 |
| Male | 46 (63.9%) | 47 (61.8%) | 67 (60.4%) | 13 (68.4%) | |||
| Performance status | ECOG 0/1 | 32 (44.4%) | 20 (26.3%) | 0.021 | 45 (40.5%) | 4 (21.1%) | 0.105 |
| ECOG ≥2 | 40 (55.6%) | 56 (73.7%) | 66 (59.5%) | 15 (78.9%) | |||
| B symptoms | Absent | 30 (41.7%) | 24 (31.6%) | 0.203 | 45 (40.5%) | 2 (10.5%) | 0.012 |
| Present | 42 (58.3%) | 52 (68.4%) | 66 (59.5%) | 17 (89.5%) | |||
| Tumor mass (cm) | <10 | 62 (86.1%) | 55 (72.4%) | 0.040 | 92 (82.9%) | 11 (57.9%) | 0.030 |
| ≥10 | 10 (13.9%) | 21 (27.6%) | 19 (17.1%) | 8 (42.1%) | |||
| Stage (Lugano) | I–II2 | 39 (41.7%) | 41 (53.9%) | 0.979 | 63 (56.8%) | 6 (31.6%) | 0.042 |
| IIE-IV | 33 (45.8%) | 35 (46.1%) | 48 (43.2%) | 13 (68.4%) | |||
| LDH | Normal | 42 (58.3%) | 44 (57.9%) | 0.895 | 65 (58.6%) | 11 (57.9%) | 0.340 |
| Increased | 26 (36.1%) | 26 (34.2%) | 39 (35.1%) | 8 (42.1%) | |||
| No data | 4 (5.6%) | 6 (7.9%) | 7 (6.3%) | 0 | |||
| Stage modified IPI | ≤2 | 38 (52.8%) | 31 (40.8%) | 0.571 | 57 (51.4%) | 6 (31.6%) | 0.103 |
| ≥3 | 34 (47.2%) | 44 (57.9%) | 53 (47.7%) | 13 (68.4%) | |||
| No data | 0 | 1 (1.3%) | 1 (0.9%) | 0 | |||
| Major involved sites | Stomach | 50 (69.4%) | 33 (43.4%) | 0.001 | 63 (56.8%) | 11 (57.9%) | 0.926 |
| Intestine | 22 (30.6%) | 43 (56.6%) | 48 (43.2%) | 8 (42.1%) | |||
| Response after treatment | Complete remission | 54 (75.0%) | 40 (52.6%) | 0.010 | 83 (74.8%) | 5 (26.3%) | 0.001 |
| Partial remission | 10 (13.9%) | 14 (18.4%) | 15 (13.5%) | 6 (31.6%) | |||
| Relapse or disease progression | 8 (11.1%) | 22 (28.9%) | 13 (11.7%) | 8 (42.1%) | |||
| Rituximab | No | NA | NA | NA | 30 (27.0%) | 4 (21.1%) | 0.791 |
| Yes | NA | NA | 81 (73.0%) | 15 (78.9%) | |||
Abbreviations: GICs, gastrointestinal complications; ECOG, Eastern Cooperative Oncology Group; LDH, lactic dehydrogenase; IPI, International Prognostic Index.